SCHEMBL30918486

SCHEMBL30918486

Cc1ccnc(CCl)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL510744 1.00
Hydrochloric Acid SCHEMBL28013142 0.98 UHRF1 (0.48)
Bromide SCHEMBL30220675 0.98 UHRF1 (0.48)
Hydrochloric Acid SCHEMBL1193641 0.98 UHRF1 (0.48)
SCHEMBL30932457 0.81 UHRF1 (0.54)
SCHEMBL12596 0.79
SCHEMBL31421768 0.79
SCHEMBL8569698 0.78 UHRF1 (0.42)
SCHEMBL1443623 0.77
SCHEMBL22685043 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 WO disclosed
CN-118159530-A Compounds for the treatment of pain, in particular neuropathic pain and/or other diseases or disorders associated with AT2R and/or AT2R mediated signalling 康福治疗有限公司 2024-06-07 CN disclosed